Clinical trials
High Grade Serous Carcinoma clinical trials
Below are recruiting high grade serous carcinoma clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT07546500RecruitingPhase 3
Azenosertib versus chemotherapy for advanced ovarian cancer
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
Phoenix, ArizonaAges 18 years+ - NCT04585958RecruitingPhase 1
DS-8201a plus olaparib for HER2-positive platinum-resistant ovarian cancer
This trial tests whether combining DS-8201a with olaparib can slow or shrink HER2-positive ovarian cancer that has returned quickly after platinum chemotherapy. It’s a Phase 1 study, meaning it mainly checks safety and finds the best dose, while also looking for signs of anti-cancer activity.
Phoenix, ArizonaAges 18 years+ - NCT05551507RecruitingPhase 1/Phase 2
Test drug IN10018 plus chemotherapy for platinum-resistant ovarian cancer
This trial tests IN10018 together with standard chemotherapy in people with high-grade serous ovarian (or related) cancer that has come back or progressed soon after platinum treatment. The goal is to see if adding IN10018 can improve cancer control and safety.
AnyangAges 18 years+ - NCT04918186RecruitingPhase 2
Immunotherapy for platinum-resistant ovarian, with tumor testing
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
Chicago, IllinoisAges 18 years+ - NCT05512208RecruitingPhase 2
Avutometinib plus defactinib for RAS or BRAF mutated gynecologic cancer
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Orlando, FloridaAges 18–99 - NCT07125391RecruitingPhase 2
Chemo plus propranolol before surgery for advanced ovarian cancer
This trial tests adding propranolol (a heart medication) to standard chemotherapy before surgery for advanced high-grade serous ovarian cancer. The goal is to see if this combination helps shrink tumors more effectively.
Hefei, AnhuiAges 18–75 - NCT05872204RecruitingPhase 2
Abemaciclib plus letrozole for rare ER-positive ovarian cancer
This trial tests whether abemaciclib with letrozole can slow or shrink certain rare ovarian cancers that have estrogen receptors. It may help people whose cancer has come back and can be measured on scans, with extra required tissue and blood tests.
Liège, LiègeAges 18 years+ - NCT05961124RecruitingPhase 2
Lower-dose niraparib to reduce interruptions in ovarian maintenance
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
Toronto, OntarioAges 18 years+ - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT05256225RecruitingPhase 3
Adding Herceptin medicines to chemo for HER2-positive endometrial cancer
This Phase 3 trial tests whether adding Herceptin Hylecta or Phesgo to standard chemotherapy works better than chemotherapy alone for HER2-positive serous endometrial cancer or carcinosarcoma. It may help by improving how well treatment controls or shrinks the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07265947RecruitingPhase 2
Testing dabogratinib for low-grade upper tract bladder cancer
This trial tests a new targeted therapy pill, dabogratinib, for people with low-grade upper tract urothelial carcinoma (a type of cancer in the tubes that carry urine from kidneys to bladder). It may be an option if you have tumor tissue left after a biopsy and haven't had certain prior treatments.
Tampa, FloridaAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT04575935RecruitingPhase 3
Minimally invasive surgery after chemotherapy for advanced ovarian cancer
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
Miami, FloridaAges 18 years+ - NCT05113368RecruitingPhase 2
Regorafenib plus fulvestrant for recurrent low-grade ovarian cancer
This trial tests whether regorafenib (a targeted pill) plus fulvestrant (an injection that lowers estrogen signaling) can slow down recurrent low-grade serous ovarian cancer. It may help people whose cancer has returned after prior treatments.
Cleveland, OhioAges 18 years+ - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT07316361Enrolling by invitationEarly Phase 1
Personalized vaccine for high-risk endometrial cancer
This trial tests a personalized vaccine made from your tumor's unique proteins to help your immune system fight high-risk or advanced endometrial cancer. It is given along with your regular cancer treatments.
Thessaloniki, ThessalonikiAges Any age
Hear when a new High Grade Serous Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high grade serous carcinoma?
- Yes. Clin2 currently lists 42 recruiting high grade serous carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high grade serous carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high grade serous carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.